A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

被引：2
|
作者：
Brivio, Erica [1 ,2 ]
Hoogendijk, Raoull [1 ]
Chantrain, Christophe [3 ]
Rialland, Fanny [4 ]
Contet, Audrey [5 ]
Elitzur, Sarah [6 ]
Dalla-Pozza, Luciano [7 ]
Kallay, Krisztian [8 ]
Li, Chi Kong [9 ]
Kato, Motohiro [10 ]
Markova, Inna V. [11 ]
Schmiegelow, Kjeld [12 ]
Bodmer, Nicole [13 ]
Pieters, Rob [1 ]
Zwaan, Christian Michel [1 ,2 ]
机构：
[1] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
[2] Erasmus MC, Dept Pediat Oncol Hematol, Sophia Childrens Hosp, Rotterdam, Netherlands
[3] CHC Liege, Clin Esperance, Div Pediat Hematol Oncol, Montegnee, Belgium
[4] CHU Nantes, Nantes, France
[5] CHRU Nancy, Childrens Hosp, Dept Hematol & Oncol, Vandoeuvre Les Nancy, France
[6] Schneider Childrens Med Ctr Israel, Pediat Hematol Oncol, Petah Tiqwa, Israel
[7] Childrens Hosp Westmead, Canc Ctr Children, Westmead, NSW, Australia
[8] Cent Hosp Southern Pest, Pediat Hematol & Stem Cell Transplantat Dept, Natl Inst Hematol & Infect Dis, Budapest, Hungary
[9] Chinese Univ Hong Kong, Dept Paediat, Prince Wales Hosp, Hong Kong, Peoples R China
[10] Natl Ctr Child Hlth & Dev, Dept Pediat Hematol & Oncol Res, Tokyo, Japan
[11] First Pavlov State Med Univ St Petersburg, Raisa Gorbacheva Mem Sci Inst Children Oncol Hema, St Petersburg, Russia
[12] Rigshosp Univ Hosp, Dept Pediat & Adolescent Med, Copenhagen, Denmark
[13] Univ Childrens Hosp Zurich, Zurich, Switzerland
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-126472
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3890
引用
收藏
页数：4
相关论文
共 50 条
  • [21] A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)
    Brivio, Erica
    Locatelli, Franco
    Lopez-Yurda, Marta
    Malone, Andrea
    Diaz-de-Heredia, Cristina
    Bielorai, Bella
    Rossig, Claudia
    van der Velden, Vincent H. J.
    Ammerlaan, Anneke C. J.
    Thano, Adriana
    van der Sluis, Inge M.
    den Boer, Monique L.
    Chen, Ying
    Sleight, Barbara
    Brethon, Benoit
    Nysom, Karsten
    Sramkova, Lucie
    Ora, Ingrid
    Vinti, Luciana
    Chen-Santel, Christiane
    Zwaan, Christian Michel
    BLOOD, 2021, 137 (12) : 1582 - 1590
  • [22] Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)
    Stelljes, Matthias
    Su, Yun
    Fahrbach, Kyle
    Vandendries, Erik
    Page, Veronique
    Onyekwere, Uchenna
    Wang, Yunyang
    Cappelleri, Joseph C.
    Proskorovsky, Irina
    BLOOD, 2017, 130
  • [23] Inotuzumab ozogamicin (CMC-544) compared to chemotherapy in patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): A retrospective comparison
    Faderl, Stefan
    Jain, Nitin
    O'Brien, Susan Mary
    Thomas, Deborah A.
    Ravandi, Farhad
    Jabbour, Elias
    Pierce, Sherry
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] WEEKLY INOTUZUMAB OZOGAMICIN (INO) IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    DeAngelo, D. J.
    Stock, W.
    Shustov, A. R.
    Ananthakrishnan, R.
    Luu, K.
    Boni, J.
    Volkert, A.
    Vandendries, E.
    Advani, A. S.
    HAEMATOLOGICA, 2013, 98 : 463 - 464
  • [25] Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain
    Torrent, Anna
    Morgades, Mireia
    Garcia-Calduch, Olga
    de Llano, Maria Paz Queipo
    Montesinos, Pau
    Navarro, Irene
    Hernandez-Rivas, Jesus Maria
    Barez-Garcia, Abelardo
    Gonzalez-Campos, Jose
    Oiartzabal, Itziar
    Valero, Marta
    Cervera, Marta
    Zudaire, Teresa
    Albors-Ferreiro, Manuel
    Lopez-Godino, Oriana
    Gil-Cortes, Cristina
    Villalon, Lucia
    Saldana, Raquel
    Ribera, Josep-Maria
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (03) : 485 - 490
  • [26] Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
    Garrett, May
    Ruiz-Garcia, Ana
    Parivar, Kourosh
    Hee, Brian
    Boni, Joseph
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2019, 46 (03) : 211 - 222
  • [27] BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN ALGERIA
    Djemai, S.
    Derki, S.
    Enzrati, Jalal J.
    Russell-Smith, T. A.
    VALUE IN HEALTH, 2024, 27 (12) : S83 - S84
  • [28] Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia
    Stock, Wendy
    Martinelli, Giovanni
    Stelljes, Matthias
    DeAngelo, Daniel J.
    Goekbuget, Nicola
    Advani, Anjali S.
    O'Brien, Susan
    Liedtke, Michaela
    Merchant, Akil A.
    Cassaday, Ryan D.
    Wang, Tao
    Zhang, Hui
    Vandendries, Erik
    Jabbour, Elias
    Marks, David, I
    Kantarjian, Hagop M.
    CANCER, 2021, 127 (06) : 905 - 913
  • [29] The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia
    Yilmaz, Musa
    Richard, Samantha
    Jabbour, Elias
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2015, 6 (05) : 253 - 261
  • [30] Results of the Compassionate Program of Inotuzumab Ozogamicin for Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia in Spain
    Ribera, Josep-Maria
    Garcia, Olga
    Montesinos, Pau
    Rodriguez-Veiga, Rebeca
    Garcia-Fortes, Maria
    Barez Garcia, Abelardo
    Oiartzabal, Itziar
    Gonzalez-Campos, Jose A.
    Mendez Sanchez, Jose Angel
    Zudaire, Maite
    Villalon, Lucia
    Lopez-Godino, Oriana
    Gil, Cristina
    Vicent, Ana
    Saldana, Raquel
    Valero, Marta
    Torrent, Anna
    Maria Hernandez-Rivas, Jesus
    BLOOD, 2021, 138
12345